Garivulimab Biosimilar – Anti-CD274 mAb – Research Grade

Garivulimab Biosimilar – Anti-CD274 mAb – Research Grade Introduction

Garivulimab Biosimilar, also known as Anti-CD274 mAb, is a research grade monoclonal antibody that targets the protein CD274, also known as programmed cell death ligand 1 (PD-L1). This antibody has shown promising results in preclinical studies and is currently being investigated as a potential therapeutic option for various diseases.

Structure of Garivulimab Biosimilar

Garivulimab Biosimilar is a recombinant humanized IgG4 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the CD274 protein, while the constant region determines the antibody’s effector functions.

The antibody is produced using recombinant DNA technology, where the gene for the variable region is inserted into a mammalian cell line, which then produces the antibody. This process ensures a high level of purity and consistency in the antibody’s structure and function.

Mechanism of Action

Garivulimab Biosimilar works by binding to the CD274 protein on the surface of cells. CD274 is a ligand for the programmed cell death protein 1 (PD-1), which is expressed on the surface of immune cells. When CD274 binds to PD-1, it inhibits the activity of immune cells, allowing cancer cells to evade the immune system and continue to grow.

By binding to CD274, Garivulimab Biosimilar blocks the interaction between CD274 and PD-1, thereby restoring the activity of immune cells and promoting an anti-tumor response. This mechanism of action is similar to that of other PD-L1 inhibitors, such as pembrolizumab and nivolumab.

Applications of Garivulimab Biosimilar

Garivulimab Biosimilar is being investigated as a potential therapeutic option for various diseases, including cancer and autoimmune disorders. The antibody’s ability to block the interaction between CD274 and PD-1 makes it a promising candidate for cancer immunotherapy.

Preclinical studies have shown that Garivulimab Biosimilar can inhibit the growth of various types of cancer cells, including lung cancer, breast cancer, and melanoma. It has also been shown to enhance the activity of other cancer treatments, such as chemotherapy and radiation therapy.

In addition to cancer, Garivulimab Biosimilar is also being studied for its potential in treating autoimmune disorders, such as rheumatoid arthritis and lupus. By inhibiting the activity of immune cells, the antibody may help to reduce inflammation and prevent further damage to tissues and organs.

Conclusion

Garivulimab Biosimilar, also known as Anti-CD274 mAb, is a research grade monoclonal antibody that targets the protein CD274. It works by blocking the interaction between CD274 and PD-1, thereby promoting an anti-tumor response and potentially treating autoimmune disorders. With promising results in preclinical studies, Garivulimab Biosimilar has the potential to become a valuable therapeutic option for various diseases.